Cas:54903-09-2 6-acetyl-3H-1,3-benzoxazol-2-one manufacturer & supplier

Chemical Name:6-acetyl-3H-1,3-benzoxazol-2-one

CAS.NO:54903-09-2

Synonyms:6-acetyl-2-oxo-3-hydrobenzoxazole;Acetyl-6 benzoxazolinone;6-acetyl-3H-benzooxazol-2-one;JPB 2

Molecular Formula:C₉H₇NO₃

Molecular Weight:177.15700

HS Code:2934999090

Physical and Chemical Properties:

Melting point:232-236ºC

Boiling point:N/A

Density:1.325g/cm3

Index of Refraction:1.577

PSA:63.07000

Exact Mass:177.04300

LogP:1.32370

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 6-acetyl-2-oxo-3-hydrobenzoxazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,JPB 2 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-acetyl-3H-benzooxazol-2-one Use and application,6-acetyl-3H-benzooxazol-2-one technical grade,usp/ep/jp grade.

Related News: As Reuters reported last month, Lilly tapped the Washington D.C. law firm Covington & Burling LLP to investigate the alleged alterations, which the employees said were meant to downplay serious quality control problems at the plant producing the drugmaker’s COVID-19 antibody treatment. 6-acetyl-3H-1,3-benzoxazol-2-one manufacturer Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). 6-acetyl-3H-1,3-benzoxazol-2-one supplier As Reuters reported last month, Lilly tapped the Washington D.C. law firm Covington & Burling LLP to investigate the alleged alterations, which the employees said were meant to downplay serious quality control problems at the plant producing the drugmaker’s COVID-19 antibody treatment. 6-acetyl-3H-1,3-benzoxazol-2-one vendor Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). 6-acetyl-3H-1,3-benzoxazol-2-one factory With nearly 194 billion US dollars of original research medicines facing the expiration of patents in the past five years, more and more domestic companies are focusing on the corresponding characteristic APIs, and have started research and development and production preparations in advance. The scale of production and export of APIs will continue to expand and grow.